CN1388760A - 在疾病治疗中作为胞毒剂,药物预致敏剂和化学致敏剂的透明质酸 - Google Patents

在疾病治疗中作为胞毒剂,药物预致敏剂和化学致敏剂的透明质酸 Download PDF

Info

Publication number
CN1388760A
CN1388760A CN01802357A CN01802357A CN1388760A CN 1388760 A CN1388760 A CN 1388760A CN 01802357 A CN01802357 A CN 01802357A CN 01802357 A CN01802357 A CN 01802357A CN 1388760 A CN1388760 A CN 1388760A
Authority
CN
China
Prior art keywords
cancer
drug
cells
hyaluronic acid
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01802357A
Other languages
English (en)
Chinese (zh)
Inventor
特蕾西·布朗
理查德·福克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alchemia Oncology Pty Ltd
Original Assignee
Meditech Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meditech Research Ltd filed Critical Meditech Research Ltd
Publication of CN1388760A publication Critical patent/CN1388760A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN01802357A 2000-07-14 2001-07-13 在疾病治疗中作为胞毒剂,药物预致敏剂和化学致敏剂的透明质酸 Pending CN1388760A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ8795A AUPQ879500A0 (en) 2000-07-14 2000-07-14 Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
AUPQ8795 2000-07-14

Publications (1)

Publication Number Publication Date
CN1388760A true CN1388760A (zh) 2003-01-01

Family

ID=3822859

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01802357A Pending CN1388760A (zh) 2000-07-14 2001-07-13 在疾病治疗中作为胞毒剂,药物预致敏剂和化学致敏剂的透明质酸

Country Status (10)

Country Link
US (3) US20030180382A1 (cg-RX-API-DMAC10.html)
EP (1) EP1301209A4 (cg-RX-API-DMAC10.html)
JP (2) JP5548328B2 (cg-RX-API-DMAC10.html)
CN (1) CN1388760A (cg-RX-API-DMAC10.html)
AU (1) AUPQ879500A0 (cg-RX-API-DMAC10.html)
CA (1) CA2382560C (cg-RX-API-DMAC10.html)
GB (1) GB2368525B (cg-RX-API-DMAC10.html)
NZ (1) NZ517359A (cg-RX-API-DMAC10.html)
WO (1) WO2002005852A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200201561B (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109512825A (zh) * 2018-12-29 2019-03-26 江苏靶标生物医药研究所有限公司 一种铂类化合物和透明质酸钠的组合物及其应用
CN109528763A (zh) * 2018-12-29 2019-03-29 江苏靶标生物医药研究所有限公司 顺铂与透明质酸钠的组合物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
CA2513143A1 (en) * 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
CA2616607C (en) 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EP1922077A4 (en) 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES
JP2007153766A (ja) * 2005-12-01 2007-06-21 Toshitsu Kagaku Kenkyusho:Kk Ｍａｐキナーゼキナーゼキナーゼ遺伝子の発現増強剤
WO2008041514A1 (ja) 2006-09-22 2008-04-10 Kochi University 放射線または抗がん化学療法増感剤
WO2009097570A2 (en) * 2008-01-30 2009-08-06 University Of Kansas Intralymphatic chemotherapy drug carriers
ES2694582T3 (es) * 2011-01-31 2018-12-21 Lucolas-M.D. Ltd. Combinaciones de inhibidores de aromatasa y antioxidantes
US9316645B2 (en) 2011-10-07 2016-04-19 Brown University Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging
US20130236504A1 (en) * 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
WO2014015264A1 (en) 2012-07-20 2014-01-23 Brown University Functionalized media and methods of making and using therefor
EP2712650A1 (en) 2012-09-27 2014-04-02 F. Hoffmann-La Roche AG Adapter and drug cartridge alignment device
EP2712651A1 (en) 2012-09-27 2014-04-02 F. Hoffmann-La Roche AG Venting device for use in ambulatory infusion system
EP2957287B1 (en) 2013-02-15 2019-04-03 KORTUC Inc. Radiation/chemotherapy sensitizer to be used for intratumoral local injection and for controlled release of hydrogen peroxide with hydrogel as carrier
AU2022220683A1 (en) * 2021-02-11 2023-08-31 Department Of Veterans Affairs Methods for preventing cancer relapse

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA612307A (en) 1961-01-10 International Business Machines Corporation Hydraulic drive tape handling system
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
CH666897A5 (fr) 1983-10-11 1988-08-31 Fidia Spa Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques.
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
CA1227427A (en) 1984-08-16 1987-09-29 Albert Landsberger Therapeutic agent for the use in cancer treatment
JPS6191986U (cg-RX-API-DMAC10.html) 1984-11-24 1986-06-14
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5202431A (en) * 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US4665107A (en) * 1986-03-21 1987-05-12 Koh-I-Noor Rapidograph, Inc. Pigment encapsulated latex aqueous colorant dispersions
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5128450A (en) * 1989-06-30 1992-07-07 Urdal David L Nonglycosylated human interleukin-3 analog proteins
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2061566C (en) 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
EP0952855B1 (en) * 1991-07-03 2005-07-27 Meditech Research Limited Use of hyaluronan in gene therapy
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
EP0563475B1 (en) * 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5287123A (en) * 1992-05-01 1994-02-15 Hewlett-Packard Company Preheat roller for thermal ink-jet printer
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
CA2089621A1 (en) * 1993-02-16 1994-08-17 Rudolf Edgar Falk Formulations containing hyaluronic acid
CA2094203A1 (en) 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
US5847002A (en) * 1993-04-16 1998-12-08 Hyal Pharmaceutical Corporation Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
AU2479695A (en) 1994-05-09 1995-11-29 Hadasit Medical Research Services & Development Company Ltd Prevention of tumor metastasis
JPH10504828A (ja) 1994-08-30 1998-05-12 ハイアル ファーマスティカル コーポレイション 細胞活性調整のためのヒアルロン酸およびその誘導体
JP2000502322A (ja) * 1995-09-14 2000-02-29 ブリストル−マイヤーズ・スクイブ・カンパニー Ｐ５３−関連腫瘍の処置におけるインスリン様成長因子結合性プロテイン３（ｉｇｆ−ｂｐ３）
WO1997010841A1 (en) * 1995-09-18 1997-03-27 The Trustees Of Columbia University In The City Of New York Antiangiogenic properties of endothelial-monocyte activating polypeptide ii
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
HUP9901935A3 (en) 1995-12-01 2001-04-28 Jagotec Ag Dosage kit for targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
DE69700887T2 (de) * 1996-01-31 2000-06-29 Nisshin Flour Milling Co., Ltd. Isoprenderivate
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CA2175282A1 (en) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
US5756537A (en) * 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
IT1286510B1 (it) 1996-11-29 1998-07-15 Cooperativa Centro Ricerche Po Esteri butirrici ad attivita' antiproliferativa e composizioni farmaceutiche che li contengono
EP0891775A4 (en) * 1996-12-27 2002-07-24 Seikagaku Kogyo Co Ltd MEDICINE FOR URBAN BLADDER DISORDERS
ATE229038T1 (de) * 1997-04-04 2002-12-15 Fidia Advanced Biopolymers Srl N-sulfatierte hyaluronsäureverbindungen, ihre derivate und verfahren zu ihrer herstellung
CA2208924A1 (en) 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
US20020015724A1 (en) * 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
JP2002526556A (ja) 1998-10-02 2002-08-20 ジェンザイム・コーポレーション 癒着の防止方法
IT1303735B1 (it) * 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
EP1140198B1 (en) * 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
IT1306643B1 (it) * 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
SE9904121D0 (sv) 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US7125858B2 (en) 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US6749865B2 (en) * 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2002068383A2 (en) * 2001-02-22 2002-09-06 Anika Therapeutics, Inc. Thiol-modified hyaluronan
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
EP1480656A4 (en) * 2002-02-15 2007-07-18 Res Dev Foundation ADENOVIRAL TRANDUCTION INDUCED BY HYALURONIC ACID
JP2004262777A (ja) 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
CA2616607C (en) 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EP1922077A4 (en) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109512825A (zh) * 2018-12-29 2019-03-26 江苏靶标生物医药研究所有限公司 一种铂类化合物和透明质酸钠的组合物及其应用
CN109528763A (zh) * 2018-12-29 2019-03-29 江苏靶标生物医药研究所有限公司 顺铂与透明质酸钠的组合物

Also Published As

Publication number Publication date
US20050267069A1 (en) 2005-12-01
CA2382560A1 (en) 2002-01-24
CA2382560C (en) 2011-05-10
EP1301209A1 (en) 2003-04-16
US8388993B2 (en) 2013-03-05
JP2004502789A (ja) 2004-01-29
US8287894B2 (en) 2012-10-16
ZA200201561B (en) 2003-11-25
JP5548328B2 (ja) 2014-07-16
GB2368525A (en) 2002-05-08
NZ517359A (en) 2003-11-28
WO2002005852A1 (en) 2002-01-24
GB0204331D0 (en) 2002-04-10
AUPQ879500A0 (en) 2000-08-10
US20060263395A1 (en) 2006-11-23
US20030180382A1 (en) 2003-09-25
JP2012162569A (ja) 2012-08-30
EP1301209A4 (en) 2005-11-09
GB2368525B (en) 2004-08-11

Similar Documents

Publication Publication Date Title
Jin et al. Iron oxide nanoparticles promote macrophage autophagy and inflammatory response through activation of toll-like Receptor-4 signaling
CN1192678A (zh) 生物药剂组合物
JP2012162569A (ja) 疾患の処置における細胞毒性物質、薬物プレ増感剤および化学増感剤としてのヒアルロナン
CN1336828A (zh) 增强药物功效的组合物和方法
CN1729012A (zh) 预防和治疗实体瘤的组合物和方法
CN1564678A (zh) 类脂化糖胺聚糖颗粒及其在诊断和治疗用药物和基因传递中的应用
CN101039682A (zh) 磺基烷基醚－烷基醚环糊精衍生物
CN1960729A (zh) 伊立替康制剂
CN1126548C (zh) 透明质酸锌抗消化性溃疡的应用
Yalikong et al. A triptolide loaded HER2-targeted nano-drug delivery system significantly suppressed the proliferation of HER2-positive and BRAF mutant colon cancer
US20200289520A1 (en) Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
Zou et al. Metabolic reprogramming by chemo-gene co-delivery nanoparticles for chemo-immunotherapy in head and neck squamous cell carcinoma
Ye et al. Esterase-responsive and size-optimized prodrug nanoparticles for effective intracranial drug delivery and glioblastoma treatment
CN1879607A (zh) 一种含水溶性药物的海藻酸钠微球血管栓塞剂和制备及应用
CN1867252A (zh) 多糖与用于癌症治疗的化疗剂的共同给药
CN1578677A (zh) 改良的治疗方案
CN1809385A (zh) 聚乙二醇化渥曼青霉素轭合物
WO2024251193A1 (zh) 通过kras突变来关联akr1c3酶表达水平及医药用途
Rodella et al. Repurposing chemotherapeutics in a hyaluronic acid-conjugate combination treatment approach for the local immunomodulation of the glioblastoma microenvironment
Deng et al. Vincristine/Volasertib polymersome injection enables high-efficiency synergistic treatment of acute lymphoblastic leukemia
CN1212623A (zh) 用哌嗪环氧乙烷衍生物诱导肿瘤细胞死亡的方法
CN1771954A (zh) 长春瑞滨脂质微球注射液及其制备方法
CN101479247A (zh) 5-脲取代的萘二甲酰亚胺衍生物、制备方法和用于治疗癌症的药物组合物
CN1863507A (zh) 含有靶向性脂质体的炎症性疾病治疗药或诊断药
CN1655818A (zh) 非肽类ccr1受体拮抗剂联合环孢菌素a治疗心脏移植排异反应

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20030101